J. Scott Applewhite / AP
The stock price of Australian biotech firm Innate Immunotherapeutics plunged 92% to about 4 cents per share Tuesday after the company's experimental multiple sclerosis drug bombed its clinical trial, STAT and Bloomberg report.
Why it matters: Republican Rep. Chris Collins of New York is Innate's largest investor, owning almost 17%, and lost about $17 million on the failed drug news. Collins has bragged about how he has attracted investors to Innate, including other Republican House members, but so much for that stock tip. Tom Price, President Trump's Health and Human Services secretary, also owned Innate stock but cashed out in February for at least $250,000 — a windfall that has raised ethics questions.